AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12661145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension
Number of subjects: 0
Study 12661145 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐1 concentrations
Number of subjects: 0
Study 10887713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (6 weeks)
Number of subjects: 92
Study 10887713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 8813864 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-on formula
Number of subjects: 100
Study 8813864 — intervention group
Group type: COMPARATOR
Intervention: Cows' milk
Number of subjects: 100
Study 1480375 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (group B)
Number of subjects: 29
Study 1480375 — intervention group
Group type: COMPARATOR
Intervention: Conventional tracheal tube (group A)
Number of subjects: 29
Study 3902379 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg bezafibrate per day
Number of subjects: 40
Study 3902379 — intervention group
Group type: COMPARATOR
Intervention: 300 mg fenofibrate per day
Number of subjects: 40
Study 31415304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy with cholangiogram within 24 hours of presentation (early group)
Number of subjects: 97
Study 31415304 — intervention group
Group type: COMPARATOR
Intervention: Control group (cholecystectomy after clinical resolution)
Number of subjects: 97
Study 30134187 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip plus GDMT
Number of subjects: 614
Study 30134187 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study 27123672 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting training (Triple P)
Number of subjects: 100
Study 27123672 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 100
Study 24878112 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed uninfected (HEU) children
Number of subjects: 327
Study 24878112 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed uninfected (HUU) children
Number of subjects: 327
Study 22242678 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg daily for 6 weeks (Control)
Number of subjects: 28
Study 22242678 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of desloratadine: 5 mg daily for the first 2 weeks, 10 mg daily for the second 2 weeks, and 20 mg daily for the final 2 weeks (Intervention)
Number of subjects: 28
Study 20489172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for stroke at age 55 years
Number of subjects: 5498
Study 20489172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for cerebral infarction at age 55 years
Number of subjects: 5498
Study 20489172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for intracerebral hemorrhage at age 55 years
Number of subjects: 5498
Study 20489172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for stroke across index ages 45, 55, and 65 years
Number of subjects: 5498
Study 18408525 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg/day (up to 300 mg/day)
Number of subjects: 406
Study 18408525 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 20 mg/day (up to 60 mg/day)
Number of subjects: 406
Study 15741037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnol bilateral facial ice packs
Number of subjects: 60
Study 15741037 — intervention group
Group type: COMPARATOR
Intervention: No cold therapy (control)
Number of subjects: 60
Study 12219851 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of positive mood in high caffeine consumers
Number of subjects: 0
Study 12219851 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing information about caffeine consumption
Number of subjects: 0
Study 12219851 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of positive mood
Number of subjects: 0
Study 10420136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.16% RBG cream
Number of subjects: 66
Study 10420136 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 66
Study 7498396 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot stimulation during walking
Number of subjects: 0
Study 7498396 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot stimulation just prior to footfall during walking
Number of subjects: 0
Study 7498396 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot stimulation immediately after footfall during walking
Number of subjects: 0
Study 7498396 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (P50-N80 complex) during gait
Number of subjects: 0
Study 7498396 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (P50-N80 complex) just after footfall
Number of subjects: 0
Study 2147235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 19
Study 2147235 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (dose adjusted to optimal plasma levels of 400-600 nM)
Number of subjects: 19
Study 2147235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6988039 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms inhaled salbutamol powder
Number of subjects: 12
Study 6988039 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms inhaled salbutamol powder
Number of subjects: 12
Study 6988039 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms inhaled salbutamol powder
Number of subjects: 12
Study 6988039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30334096 — intervention group
Group type: EXPERIMENTAL
Intervention: GLE/PIB treatment for 12 weeks
Number of subjects: 30
Study 28350758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal gel containing 50μg estriol for 12 weeks (group A)
Number of subjects: 75
Study 28350758 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol vaginal gel after surgery (group A1)
Number of subjects: 75
Study 28350758 — intervention group
Group type: COMPARATOR
Intervention: No estrogen treatment (group B)
Number of subjects: 75
Study 28350758 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol treatment after surgery (group A1)
Number of subjects: 75
Study 28350758 — intervention group
Group type: EXPERIMENTAL
Intervention: No estriol treatment after surgery (group A2)
Number of subjects: 75
Study 25293727 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with external beam radiotherapy (EBRT) (45-50.4 Gy)
Number of subjects: 95
Study 25293727 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without external beam radiotherapy (EBRT)
Number of subjects: 95
Study 25293727 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with pre-anastomosis intraoperative electron radiation therapy (IOERT) boost (10-15 Gy)
Number of subjects: 95
Study 25293727 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with external beam radiotherapy (EBRT)
Number of subjects: 95
Study 23803042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger supplement (750 mg per capsule, 4 capsules daily for 6 weeks)
Number of subjects: 40
Study 23803042 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (4 times a week for 6 weeks, intensity ranging from 50% to 75% of heart rate reserve)
Number of subjects: 40
Study 23803042 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise + Ginger supplement
Number of subjects: 40
Study 23803042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22292254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2), initiated within 1-3 days post-surgery, for at least 20 sessions (one session per day)
Number of subjects: 120
Study 22292254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 120
Study 19114904 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice and video demonstration and feedback (video group, n = 43)
Number of subjects: 96
Study 19114904 — intervention group
Group type: COMPARATOR
Intervention: Voice instruction alone (voice group, n = 53)
Number of subjects: 96
Study 16725234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine Twinrix (GSK)
Number of subjects: 0
Study 16725234 — intervention group
Group type: COMPARATOR
Intervention: Co-administered hepatitis A vaccine, Havrix (GSK) + hepatitis B vaccine Engerix-B (GSK)
Number of subjects: 0
Study 16725234 — intervention group
Group type: COMPARATOR
Intervention: Co-administered hepatitis A vaccine, Vaqta (Sanofi-Pasteur MSD) + hepatitis B vaccine HB VAX PRO (Sanofi-Pasteur MSD)
Number of subjects: 0
Study 15540757 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation (HoLEP)
Number of subjects: 100
Study 15540757 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study 11479155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure patients (23 patients)
Number of subjects: 105
Study 11479155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with serum creatinine > 6 mg/dL (12 patients)
Number of subjects: 105
Study 11479155 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance hemodialysis (MHD) patients (26 patients)
Number of subjects: 105
Study 11479155 — intervention group
Group type: EXPERIMENTAL
Intervention: MHD patients with therapy longer than 10 years (8 patients)
Number of subjects: 105
Study 11479155 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance hemodiafiltration patients (15 patients)
Number of subjects: 105
Study 11479155 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 healthy subjects)
Number of subjects: 105
Study 10096818 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Gortex bags, high-powered vacuum cleaner, benzyl alcohol and tannic acid spray)
Number of subjects: 48
Study 10096818 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (light cotton bags, cheap vacuum cleaner, water spray)
Number of subjects: 48
Study 7995325 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-oestradiol (9 mg)
Number of subjects: 29
Study 7995325 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg)
Number of subjects: 29
Study 7995325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3281365 — intervention group
Group type: EXPERIMENTAL
Intervention: Emcyt
Number of subjects: 220
Study 3281365 — intervention group
Group type: COMPARATOR
Intervention: flutamide
Number of subjects: 220
Study 3281365 — intervention group
Group type: EXPERIMENTAL
Intervention: Emcyt and flutamide
Number of subjects: 220
Study 7646627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 8
Study 7646627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 519960 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms orally)
Number of subjects: 5
Study 519960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31743071 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (YBLI)
Number of subjects: 260
Study 31743071 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention (DI)
Number of subjects: 260
Study 30712745 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lavender essential oil inhalation for 20 minutes every night for one month
Number of subjects: 62
Study 30712745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water) inhalation for 20 minutes every night for one month
Number of subjects: 62
Study 28584187 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 501
Number of subjects: 526
Study 28584187 — intervention group
Group type: COMPARATOR
Intervention: adalimumab (40 mg every 2 weeks)
Number of subjects: 526
Study 28629293 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jieyu capsule
Number of subjects: 149
Study 28629293 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 149
Study 24934402 — intervention group
Group type: EXPERIMENTAL
Intervention: MAT-Fel d 1 vaccine
Number of subjects: 0
Study 23115771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser irradiation at a wavelength of 810 nm and an output power of 2 W for 5 × 5 seconds (Subgroup A)
Number of subjects: 60
Study 23115771 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (Subgroup B)
Number of subjects: 60
Study 23115771 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 60
Study 23115771 — intervention group
Group type: EXPERIMENTAL
Intervention: BioPure MTAD
Number of subjects: 60
Study 19923515 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex-It stylet (FIS)
Number of subjects: 80
Study 19923515 — intervention group
Group type: COMPARATOR
Intervention: Malleable stylet (control)
Number of subjects: 80
Study 17868757 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based treatment protocols
Number of subjects: 0
Study 17868757 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR*D study
Number of subjects: 0
Study 14551893 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE
Number of subjects: 99
Study 14551893 — intervention group
Group type: COMPARATOR
Intervention: YF-VAX
Number of subjects: 99
Study 11097537 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (sufficient to eliminate brain electrical activity as measured on EEG)
Number of subjects: 24
Study 11097537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 24
Study 8899386 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected length of the ROC curve (PLC)
Number of subjects: 0
Study 8899386 — intervention group
Group type: EXPERIMENTAL
Intervention: Area swept out by the ROC curve (ASC)
Number of subjects: 0
Study 8899386 — intervention group
Group type: COMPARATOR
Intervention: Area under the curve (AUC)
Number of subjects: 0
Study 1423468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 m walking test
Number of subjects: 38
Study 1423468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 m running time
Number of subjects: 38
Study 2864530 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to rest in hospital from 32 weeks' gestation until delivery
Number of subjects: 212
Study 2864530 — intervention group
Group type: COMPARATOR
Intervention: Control group offered selective hospital admission, on average, 5 weeks later
Number of subjects: 212
Study 31677042 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Ketogenic Diet (KD)
Number of subjects: 45
Study 31677042 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 45
Study 31677042 — intervention group
Group type: COMPARATOR
Intervention: Comparison of KD and MAD
Number of subjects: 45
Study 31480601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (oral solution of pregabalin 150 mg twice daily for 14 days)
Number of subjects: 43
Study 31480601 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 43
Study 31480601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 43
Study 31480601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27876198 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent rotavirus vaccine (RV1)
Number of subjects: 0
Study 27876198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 0
Study 27876198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 26410675 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience Training (RT)
Number of subjects: 40
Study 23243253 — intervention group
Group type: COMPARATOR
Intervention: 0% corn DDGS
Number of subjects: 240
Study 23243253 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% corn DDGS
Number of subjects: 240
Study 23243253 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% corn DDGS
Number of subjects: 240
Study 23243253 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% corn DDGS
Number of subjects: 240
Study 23243253 — intervention group
Group type: EXPERIMENTAL
Intervention: All DDGS diets
Number of subjects: 240
Study 20152998 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + GLP-1
Number of subjects: 10
Study 20152998 — intervention group
Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 10
Study 20152998 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 10
Study 19239577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture device
Number of subjects: 119
Study 19239577 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 119
Study 17043639 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-gene prognosis predictor (PP) based on non-neoplastic mucosa microarray gene expression
Number of subjects: 24
Study 15487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe recognition paradigm with a memory set of three pure tones followed by a probe tone.
Number of subjects: 0
Study 15487440 — intervention group
Group type: EXPERIMENTAL
Intervention: Suffix sound presented 1 second after the third sound in the memory set.
Number of subjects: 0
Study 11371279 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDCAB with LITA to LAD
Number of subjects: 8
Study 9244203 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/d for 3 days or 500 mg/d for 6 days)
Number of subjects: 213
Study 9244203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 9244203 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Cp+ve-NR group)
Number of subjects: 213
Study 9244203 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 213
Study 8310466 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term outpatient treatment in alcoholics with previous suicidal behavior
Number of subjects: 72
Study 2939574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 46
Study 2939574 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium 0.25 mg/kg
Number of subjects: 46
Study 30202946 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Number of subjects: 289
Study 30202946 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 289
Study 30202946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omega-3 and losartan
Number of subjects: 289
Study 28801396 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable anchored single-incision mini-slings (SIMS)
Number of subjects: 0
Study 28801396 — intervention group
Group type: COMPARATOR
Intervention: Standard tension-free midurethral slings (SMUS)
Number of subjects: 0
Study 28801396 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 25735918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemfola (150 IU daily)
Number of subjects: 372
Study 25735918 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f (150 IU daily)
Number of subjects: 372
Study 25735918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemfola
Number of subjects: 372
Study 25735918 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f
Number of subjects: 372
Study 23967725 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy
Number of subjects: 1
Study 23967725 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine conjugated with a new biological agent
Number of subjects: 1
Study 21700245 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI using tenecteplase (Group A)
Number of subjects: 162
Study 21700245 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI (Group B)
Number of subjects: 162
Study 19332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 2776
Study 19332456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776
Study 16733692 — intervention group
Group type: EXPERIMENTAL
Intervention: Erb:YAG goniotomy
Number of subjects: 40
Study 16733692 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 40
Study 15536856 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Fill MH (Megadenta)
Number of subjects: 134
Study 15536856 — intervention group
Group type: COMPARATOR
Intervention: Helio Progress (Vivadent)
Number of subjects: 134
Study 15536856 — intervention group
Group type: COMPARATOR
Intervention: Visio-Dispers (ESPE)
Number of subjects: 134
Study 11265901 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure plus a children's book
Number of subjects: 43
Study 11265901 — intervention group
Group type: COMPARATOR
Intervention: Brochure alone
Number of subjects: 43
Study 9631846 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) membrane
Number of subjects: 16
Study 9631846 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membrane
Number of subjects: 16
Study 3068160 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg) + Rosaprostol (2 g) daily
Number of subjects: 44
Study 3068160 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg) + Placebo
Number of subjects: 44
Study 3068160 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (diclofenac sodium 50 mg, piroxicam 20 mg, acetylsalicylic acid 500 mg)
Number of subjects: 44
Study 3068160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosaprostol (2 g)
Number of subjects: 44
Study 31385912 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 34
Study 31385912 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity aerobic exercise
Number of subjects: 34
Study 31385912 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training intervention (12 weeks)
Number of subjects: 34
Study 28937272 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement music therapy (MMT) group, 35 participants
Number of subjects: 45
Study 28937272 — intervention group
Group type: COMPARATOR
Intervention: Control STT group, 10 participants
Number of subjects: 45
Study 27627596 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse (alcohol-free mouthrinse containing 0.7% cetylpyridinium chloride)
Number of subjects: 466